• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用 2002 年至 2004 年的国家行政医疗保健数据和捕获-再捕获方法估计美国肌萎缩侧索硬化症的患病率。

Estimation of the Prevalence of Amyotrophic Lateral Sclerosis in the United States Using National Administrative Healthcare Data from 2002 to 2004 and Capture-Recapture Methodology.

机构信息

Department of Health Research and Policy, Stanford School of Medicine, Stanford, California,

Department of Health Research and Policy, Stanford School of Medicine, Stanford, California, USA.

出版信息

Neuroepidemiology. 2018;51(3-4):149-157. doi: 10.1159/000488798. Epub 2018 Aug 9.

DOI:10.1159/000488798
PMID:30092573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6250049/
Abstract

BACKGROUND

National administrative healthcare data may be used as a case-finding method for prevalence studies of chronic disease in the United States, but the completeness of ascertainment likely varies depending on the disease under study.

METHODS

We used 3 case-finding sources (Medicare, Medicaid, and Veterans Administration data) to estimate the prevalence of amyotrophic lateral sclerosis (ALS) in the United States for 2002-2004, and applied the capture-recapture methodology to estimate the degree of under-ascertainment when relying solely on these sources for case identification.

RESULTS

Case-finding completeness was 76% overall and did not vary by race, but was lower for males (77%) than for females (88%), and lower for patients under age 65 (66%) than patients over age 65 (79%). The uncorrected ALS prevalence ratio was 2.8/100,000 in 2002, 3.3/100,000 in 2003, and 3.7/100,000 in 2004. After correcting for under-ascertainment, the annual prevalence increased by approximately 1 per 100,000 to 3.7/100,000 in 2002 (95% CI 3.66-3.80), 4.4/100,000 in 2003 (95% CI 4.34-4.50), and 4.8/100,000 in 2004 (95% CI 4.76-4.91).

CONCLUSIONS

Federal healthcare claims databases ascertained are a very efficient method for identifying the majority of ALS-prevalent cases in the National ALS Registry, and may be enhanced by having patients self-register through the registry web portal.

摘要

背景

美国的国家行政医疗保健数据可用作慢性病患病率研究的病例发现方法,但根据所研究的疾病,确定的完整性可能有所不同。

方法

我们使用 3 种病例发现来源(医疗保险、医疗补助和退伍军人管理局数据)来估计美国 2002-2004 年肌萎缩侧索硬化症(ALS)的患病率,并应用捕获-再捕获方法来估计仅依靠这些来源进行病例识别时的未发现程度。

结果

病例发现的完整性总体上为 76%,与种族无关,但男性(77%)低于女性(88%),65 岁以下患者(66%)低于 65 岁以上患者(79%)。未校正的 ALS 患病率比为 2002 年每 100,000 人 2.8 例,2003 年每 100,000 人 3.3 例,2004 年每 100,000 人 3.7 例。校正未发现后,每年的患病率增加约 1 例,至 2002 年为每 100,000 人 3.7 例(95%CI 3.66-3.80),2003 年为每 100,000 人 4.4 例(95%CI 4.34-4.50),2004 年为每 100,000 人 4.8 例(95%CI 4.76-4.91)。

结论

联邦医疗保健索赔数据库确定的病例是识别国家 ALS 登记处大多数 ALS 流行病例的非常有效的方法,并且可以通过登记处网络门户让患者自行登记来增强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/27f4429d479d/nihms-993528-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/6576da853ebd/nihms-993528-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/71bac283fc50/nihms-993528-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/221240a2a886/nihms-993528-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/27f4429d479d/nihms-993528-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/6576da853ebd/nihms-993528-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/71bac283fc50/nihms-993528-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/221240a2a886/nihms-993528-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42ac/6250049/27f4429d479d/nihms-993528-f0004.jpg

相似文献

1
Estimation of the Prevalence of Amyotrophic Lateral Sclerosis in the United States Using National Administrative Healthcare Data from 2002 to 2004 and Capture-Recapture Methodology.使用 2002 年至 2004 年的国家行政医疗保健数据和捕获-再捕获方法估计美国肌萎缩侧索硬化症的患病率。
Neuroepidemiology. 2018;51(3-4):149-157. doi: 10.1159/000488798. Epub 2018 Aug 9.
2
Evaluation of the Completeness of ALS Case Ascertainment in the US National ALS Registry: Application of the Capture-Recapture Method.应用捕获-再捕获法评价美国国家肌萎缩侧索硬化症注册中心肌萎缩侧索硬化症病例确定的完整性
Neuroepidemiology. 2022;56(2):104-114. doi: 10.1159/000521591. Epub 2021 Dec 20.
3
Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017.使用既定和新颖方法在美国评估肌萎缩性侧索硬化症的患病率,2017 年。
Amyotroph Lateral Scler Frontotemporal Degener. 2023 Feb;24(1-2):108-116. doi: 10.1080/21678421.2022.2059380. Epub 2022 Apr 15.
4
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013.肌萎缩侧索硬化症的患病率 - 美国,2012-2013 年。
MMWR Surveill Summ. 2016 Aug 5;65(8):1-12. doi: 10.15585/mmwr.ss6508a1.
5
Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011.2010 - 2011年美国肌萎缩侧索硬化症的患病率
MMWR Suppl. 2014 Jul 25;63(7):1-14.
6
Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016.2016年美国肌萎缩侧索硬化症(ALS)的患病率
Amyotroph Lateral Scler Frontotemporal Degener. 2022 May;23(3-4):220-225. doi: 10.1080/21678421.2021.1949021. Epub 2021 Aug 23.
7
Utility of capture-recapture methodology to assess completeness of amyotrophic lateral sclerosis case ascertainment.捕获-再捕获法在评估肌萎缩侧索硬化症病例确定完整性中的应用。
Neuroepidemiology. 2013;40(2):133-41. doi: 10.1159/000342156. Epub 2012 Oct 24.
8
Prevalence of amyotrophic lateral sclerosis in the United States, 2018.2018年美国肌萎缩侧索硬化症的患病率
Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug 21:1-7. doi: 10.1080/21678421.2023.2245858.
9
Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016.2014-2016 年美国肌萎缩侧索硬化症发病率。
Amyotroph Lateral Scler Frontotemporal Degener. 2022 Aug;23(5-6):378-382. doi: 10.1080/21678421.2021.2023190. Epub 2022 Jan 13.
10
Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data.国家肌萎缩侧索硬化症(ALS)登记处危险因素调查数据的初步结果。
PLoS One. 2016 Apr 28;11(4):e0153683. doi: 10.1371/journal.pone.0153683. eCollection 2016.

引用本文的文献

1
An Evidence Map of the Women Veterans' Health Literature, 2016 to 2023: A Systematic Review.2016年至2023年女性退伍军人健康文献证据图谱:一项系统综述
JAMA Netw Open. 2025 Apr 1;8(4):e256372. doi: 10.1001/jamanetworkopen.2025.6372.
2
Estimating prevalence of post-war health disorders using multiple systems data.利用多系统数据估计战后健康障碍的患病率。
Sci Rep. 2024 Jun 26;14(1):14763. doi: 10.1038/s41598-024-65478-3.
3
Global Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review.全球肌萎缩侧索硬化症的患病率和发病率:一项系统评价。

本文引用的文献

1
Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease.基于人群的神经退行性疾病登记册的益处、陷阱及未来设计
Neurology. 2017 Jun 13;88(24):2321-2329. doi: 10.1212/WNL.0000000000004038. Epub 2017 May 17.
2
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013.肌萎缩侧索硬化症的患病率 - 美国,2012-2013 年。
MMWR Surveill Summ. 2016 Aug 5;65(8):1-12. doi: 10.15585/mmwr.ss6508a1.
3
State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance.基于州和大都市地区的肌萎缩侧索硬化症(ALS)监测。
Neurology. 2023 Aug 8;101(6):e613-e623. doi: 10.1212/WNL.0000000000207474. Epub 2023 Jun 12.
4
A new method for estimating under-recruitment of a patient registry: a case study with the Ohio Registry of Amyotrophic Lateral Sclerosis.一种估计患者登记处招募不足的新方法:以俄亥俄州肌萎缩侧索硬化症登记处为例的案例研究。
Sci Rep. 2022 Aug 30;12(1):14721. doi: 10.1038/s41598-022-18944-9.
5
How Molecular Topology Can Help in Amyotrophic Lateral Sclerosis (ALS) Drug Development: A Revolutionary Paradigm for a Merciless Disease.分子拓扑学如何助力肌萎缩侧索硬化症(ALS)药物研发:一种针对无情疾病的革命性范式
Pharmaceuticals (Basel). 2022 Jan 14;15(1):94. doi: 10.3390/ph15010094.
6
Hydrogen Peroxide and Amyotrophic Lateral Sclerosis: From Biochemistry to Pathophysiology.过氧化氢与肌萎缩侧索硬化症:从生物化学到病理生理学
Antioxidants (Basel). 2021 Dec 27;11(1):52. doi: 10.3390/antiox11010052.
7
Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.免疫与肌萎缩侧索硬化症的相互作用:临床影响。
Neurosci Biobehav Rev. 2021 Aug;127:958-978. doi: 10.1016/j.neubiorev.2021.06.027. Epub 2021 Jun 19.
8
The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016-2018: The Ohio Population-Based ALS Registry.2016-2018 年俄亥俄州肌萎缩侧索硬化症发病率:俄亥俄州人群为基础的肌萎缩侧索硬化症登记处。
Neuroepidemiology. 2021;55(3):196-205. doi: 10.1159/000515103. Epub 2021 Apr 26.
9
Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia.估计西班牙两个地区(加泰罗尼亚和瓦伦西亚)的运动神经元疾病的患病率和发病率。
Sci Rep. 2021 Mar 18;11(1):6207. doi: 10.1038/s41598-021-85395-z.
10
Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.评估在退伍军人医疗保健系统中使用依达拉奉治疗肌萎缩侧索硬化症的使用情况和安全性。
JAMA Netw Open. 2020 Oct 1;3(10):e2014645. doi: 10.1001/jamanetworkopen.2020.14645.
Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1-2):128-34. doi: 10.3109/21678421.2015.1074699. Epub 2015 Sep 23.
4
Updated Prevalence and Demographic Characteristics for ALS Cases in Texas, 2009-2011.2009 - 2011年德克萨斯州肌萎缩侧索硬化症病例的最新患病率及人口统计学特征
South Med J. 2015 Aug;108(8):483-6. doi: 10.14423/SMJ.0000000000000324.
5
Results of Florida's Amyotrophic Lateral Sclerosis Surveillance Project, 2009-2011.佛罗里达州肌萎缩侧索硬化症监测项目(2009 - 2011年)的结果
BMJ Open. 2015 Apr 21;5(4):e007359. doi: 10.1136/bmjopen-2014-007359.
6
Population-based surveillance of amyotrophic lateral sclerosis in New Jersey, 2009-2011.2009 - 2011年新泽西州肌萎缩侧索硬化症的基于人群的监测
Neuroepidemiology. 2014;43(1):49-56. doi: 10.1159/000365850. Epub 2014 Oct 16.
7
Quantifying a nonnotifiable disease in the United States: the National Amyotrophic Lateral Sclerosis Registry model.在美国对一种非法定报告疾病进行量化:国家肌萎缩侧索硬化症登记模型。
JAMA. 2014 Sep 17;312(11):1097-8. doi: 10.1001/jama.2014.9799.
8
Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011.2010 - 2011年美国肌萎缩侧索硬化症的患病率
MMWR Suppl. 2014 Jul 25;63(7):1-14.
9
Feasibility of creating a National ALS Registry using administrative data in the United States.利用美国行政数据创建全国肌萎缩侧索硬化症登记处的可行性。
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):433-9. doi: 10.3109/21678421.2014.887119. Epub 2014 Mar 6.
10
Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues.肌萎缩侧索硬化症的描述性流行病学:新证据与未解决的问题
J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):6-11. doi: 10.1136/jnnp.2006.104828.